ImmunoCellular Therapeutics, Ltd.(NYSE Amex Equities : IMUC)
(
)
Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| GILD | Gilead Sciences, Inc. | 1.98% | 81.59 | 0.9% | $637.74m | |
| CELG | Celgene Corporation | -0.88% | 135.96 | 1.1% | $563.57m | |
| AMGN | Amgen Inc. | -1.16% | 184.12 | 1.1% | $451.54m | |
| BIIB | Biogen Inc. | -0.63% | 342.42 | 1.2% | $397.97m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 0.36% | 440.94 | 2.7% | $313.46m | |
| ALNY | Alnylam Pharmaceuticals, Inc | -1.63% | 115.63 | 10.7% | $252.14m | |
| VRTX | Vertex Pharmaceuticals Incorporated | -0.10% | 154.60 | 1.9% | $218.27m | |
| INCY | Incyte Corporation | -0.76% | 114.27 | 2.5% | $205.56m | |
| ALXN | Alexion Pharmaceuticals, Inc. | 0.16% | 140.46 | 1.9% | $180.37m | |
| EXEL | Exelixis, Inc. | -0.25% | 27.46 | 6.5% | $136.95m | |
| ILMN | Illumina, Inc. | -0.21% | 205.18 | 3.5% | $132.63m | |
| BLUE | Bluebird Bio, Inc. | 0.25% | 139.45 | 17.3% | $114.79m | |
| BMRN | BioMarin Pharmaceutical Inc. | -0.55% | 88.13 | 4.4% | $113.12m | |
| SRPT | Sarepta Therapeutics, Inc. | -1.36% | 50.72 | 16.9% | $105.98m | |
| CLVS | Clovis Oncology, Inc. | -2.48% | 76.77 | 16.5% | $102.15m |
Company Profile
ImmunoCellular Therapeutics, Ltd. is a clinical-stage company, which engages in the development of immune-based therapies for the treatment of cancers. The company's lead product candidate, ICT-107, is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. Its pipeline also includes ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T cells. The company was founded on January 31, 2006 and is headquartered in Calabasas, CA.